BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 27974666)

  • 1. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.
    Suárez-Calvet M; Araque Caballero MÁ; Kleinberger G; Bateman RJ; Fagan AM; Morris JC; Levin J; Danek A; Ewers M; Haass C;
    Sci Transl Med; 2016 Dec; 8(369):369ra178. PubMed ID: 27974666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.
    Suárez-Calvet M; Kleinberger G; Araque Caballero MÁ; Brendel M; Rominger A; Alcolea D; Fortea J; Lleó A; Blesa R; Gispert JD; Sánchez-Valle R; Antonell A; Rami L; Molinuevo JL; Brosseron F; Traschütz A; Heneka MT; Struyfs H; Engelborghs S; Sleegers K; Van Broeckhoven C; Zetterberg H; Nellgård B; Blennow K; Crispin A; Ewers M; Haass C
    EMBO Mol Med; 2016 May; 8(5):466-76. PubMed ID: 26941262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid sTREM2 in Alzheimer's Disease Is Associated with Both Amyloid and Tau Pathologies but not with Cognitive Status.
    Li TR; Lyu DY; Liu FQ;
    J Alzheimers Dis; 2022; 90(3):1123-1138. PubMed ID: 36213998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.
    Henjum K; Almdahl IS; Årskog V; Minthon L; Hansson O; Fladby T; Nilsson LN
    Alzheimers Res Ther; 2016 Apr; 8(1):17. PubMed ID: 27121148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.
    Rauchmann BS; Schneider-Axmann T; Alexopoulos P; Perneczky R;
    Neurobiol Aging; 2019 Feb; 74():182-190. PubMed ID: 30458365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
    Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model.
    Zhong L; Xu Y; Zhuo R; Wang T; Wang K; Huang R; Wang D; Gao Y; Zhu Y; Sheng X; Chen K; Wang N; Zhu L; Can D; Marten Y; Shinohara M; Liu CC; Du D; Sun H; Wen L; Xu H; Bu G; Chen XF
    Nat Commun; 2019 Mar; 10(1):1365. PubMed ID: 30911003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the minimal active soluble TREM2 sequence for modulating microglial phenotypes and amyloid pathology.
    Sheng X; Yao Y; Huang R; Xu Y; Zhu Y; Chen L; Zhang L; Wang W; Zhuo R; Can D; Chang CF; Zhang YW; Xu H; Bu G; Zhong L; Chen XF
    J Neuroinflammation; 2021 Dec; 18(1):286. PubMed ID: 34893068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TREM2 ectodomain and its soluble form in Alzheimer's disease.
    Yang J; Fu Z; Zhang X; Xiong M; Meng L; Zhang Z
    J Neuroinflammation; 2020 Jul; 17(1):204. PubMed ID: 32635934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF sTREM2 in delirium-relation to Alzheimer's disease CSF biomarkers Aβ42, t-tau and p-tau.
    Henjum K; Quist-Paulsen E; Zetterberg H; Blennow K; Nilsson LNG; Watne LO
    J Neuroinflammation; 2018 Nov; 15(1):304. PubMed ID: 30390679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology.
    Winfree RL; Nolan E; Dumitrescu L; Blennow K; Zetterberg H; Gifford KA; Pechman KR; Seto M; Petyuk VA; Wang Y; Schneider J; Bennett DA; Jefferson AL; Hohman TJ;
    Mol Neurodegener; 2024 May; 19(1):41. PubMed ID: 38760857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study.
    Ma LZ; Tan L; Bi YL; Shen XN; Xu W; Ma YH; Li HQ; Dong Q; Yu JT
    Mol Neurodegener; 2020 Apr; 15(1):25. PubMed ID: 32276587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal Fluid sTREM2 Has Paradoxical Association with Brain Structural Damage Rate in Early- and Late-Stage Alzheimer's Disease.
    Leng F; Zhan Z; Sun Y; Liu F; Edison P; Sun Y; Wang Z;
    J Alzheimers Dis; 2022; 88(1):117-126. PubMed ID: 35491791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.
    Piccio L; Deming Y; Del-Águila JL; Ghezzi L; Holtzman DM; Fagan AM; Fenoglio C; Galimberti D; Borroni B; Cruchaga C
    Acta Neuropathol; 2016 Jun; 131(6):925-33. PubMed ID: 26754641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease.
    Wang ZB; Ma YH; Sun Y; Tan L; Wang HF; Yu JT;
    J Neuroinflammation; 2022 Dec; 19(1):316. PubMed ID: 36578067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
    Morenas-Rodríguez E; Li Y; Nuscher B; Franzmeier N; Xiong C; Suárez-Calvet M; Fagan AM; Schultz S; Gordon BA; Benzinger TLS; Hassenstab J; McDade E; Feederle R; Karch CM; Schlepckow K; Morris JC; Kleinberger G; Nellgard B; Vöglein J; Blennow K; Zetterberg H; Ewers M; Jucker M; Levin J; Bateman RJ; Haass C;
    Lancet Neurol; 2022 Apr; 21(4):329-341. PubMed ID: 35305339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease.
    Park SH; Lee EH; Kim HJ; Jo S; Lee S; Seo SW; Park HH; Koh SH; Lee JH
    Sci Rep; 2021 Jun; 11(1):13050. PubMed ID: 34158530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The
    Deming Y; Filipello F; Cignarella F; Cantoni C; Hsu S; Mikesell R; Li Z; Del-Aguila JL; Dube U; Farias FG; Bradley J; Budde J; Ibanez L; Fernandez MV; Blennow K; Zetterberg H; Heslegrave A; Johansson PM; Svensson J; Nellgård B; Lleo A; Alcolea D; Clarimon J; Rami L; Molinuevo JL; Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Ewers M; Harari O; Haass C; Brett TJ; Benitez BA; Karch CM; Piccio L; Cruchaga C
    Sci Transl Med; 2019 Aug; 11(505):. PubMed ID: 31413141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.